Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1658-1669

  Samuraki, Miharu ^a   Matsunari, Ichiro ^b   Chen, Wei Ping ^b   Yajima, Kazuyoshi ^b   Yanase, Daisuke ^a   Fujikawa, Akihiko ^b   Takeda, Nozomi ^b   Nishimura, Shintaro ^b   Matsuda, Hiroshi ^c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Medical and Pharmacological Research Center Foundation   (Japan)

^c SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alzheimer's disease; Cortical atrophy; FDG; Hippocampus; PVE

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGING; MALE; METHODOLOGY; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARTIFACTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34748826802     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0454-x     Document Type: Article

References (46)

1. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
2. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
3. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-13.
4. Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79-89.
5. 18F-FDG PET: a validation study. J Nucl Med 2005;46:1633-41.
6. Ibáñez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-93.
7. Matsuda H, Ohnishi T, Asada T, Li ZJ, Kanetaka H, Imabayashi E, et al. Correction for partial-volume effects on brain perfusion SPECT in healthy men. J Nucl Med 2003;44:1243-52.
8. Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005;32:794-805.
9. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11:805-21.
10. Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging 2004;14:11S-9S.
11. May A. The role of imaging in the pathophysiology and diagnosis of headache. Curr Opin Neurol 2005;18:293-7.
12. Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O'Brien JT, Scheltens P, et al. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage 2003;18:895-907.
13. Ishii K, Sasaki H, Kono AK, Miyamoto N, Fukuda T, Mori E. Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2005;32:959-63.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
15. Berg L. Clinical dementia rating. Br J Psychiatry 1984;145:339.
16. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme Medical, 1988.
17. Frith CD, Friston K, Ashburner J, Holmes A, Poline J, Worsley K, et al. Principles and methods. In: Frackowiak RSJ, Friston KJ, Frith C, Dolan R, Mazziotta J, editors. Human brain function. San Diego: Academic; 1997. p. 3-159.
18. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997;38:925-8.
19. 99mTc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage 2002;17:1193-202.
20. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21-36.
21. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454-61.
22. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053-65.
23. 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001;42:548-57.
24. Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 1977;37:111-8.
25. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-70.
26. Ball MJ, Fisman M, Hachinski V, Blume W, Fox A, Kral VA, et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet 1985;1:14-6.
27. Ouchi Y, Nobezawa S, Okada H, Yoshikawa E, Futatsubashi M, Kaneko M. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136-42.
28. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39.
29. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860-7.
30. Jagust WJ. Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Ann N Y Acad Sci 1996;777:30-6.
31. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:317-22.
32. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
33. Horwitz B. Neuroplasticity and the progression of Alzheimer's disease. Int J Neurosci 1988;41:1-14.
34. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987;78:151-64.
35. Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 1995;2:148-56.
36. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990;11:29-37.
37. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 1985;230:1179-81.
38. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005;65:404-11.
39. Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol 1987;264:356-95.
40. Munoz M, Insausti R. Cortical efferents of the entorhinal cortex and the adjacent parahippocampal region in the monkey (Macaca fascicularis). Eur J Neurosci 2005;22:1368-88.
41. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851-9.
42. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994;344:769-72.
43. Hof PR, Bussiere T, Gold G, Kovari E, Giannakopoulos P, Bouras C, et al. Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropathol Exp Neurol 2003;62:55-67.
44. Rasmusson DX, Brandt J, Steele C, Hedreen JC, Troncoso JC, Folstein MF. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 1996;10:180-8.
45. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226:315-36.
46. Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging 2006;33:210-21.